• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

F-氟吡拉达 PET 自动灌注定量系统的开发、诊断性能和观察者间一致性。

Development, diagnostic performance, and interobserver agreement of a F-flurpiridaz PET automated perfusion quantitation system.

机构信息

Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

Department of Radiology and Imaging Sciences, Emory University Hospital, Emory University School of Medicine, Atlanta, GA, USA.

出版信息

J Nucl Cardiol. 2022 Apr;29(2):698-708. doi: 10.1007/s12350-020-02335-6. Epub 2020 Sep 7.

DOI:10.1007/s12350-020-02335-6
PMID:32895856
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7936994/
Abstract

BACKGROUND

Computerized methodologies standardize the myocardial perfusion imaging (MPI) interpretation process.

METHODS

To develop an automated relative perfusion quantitation approach for F-flurpiridaz, PET MPI studies from all phase III trial participants of F-flurpiridaz were divided into 3 groups. Count distributions were obtained in N = 40 normal patients undergoing pharmacological or exercise stress. Then, N = 90 additional studies were selected in a derivation group. Following receiver operating characteristic curve analysis, various standard deviations below the mean normal were used as cutoffs for significant CAD, and interobserver variability determined. Finally, diagnostic performance was compared between blinded visual readers and blinded derivations of automated relative quantitation in the remaining N = 548 validation patients.

RESULTS

Both approaches yielded comparable accuracies for the detection of global CAD, reaching 71% and 72% by visual reads, and 72% and 68% by automated relative quantitation, when using CAD ≥ 70% or ≥ 50% stenosis for significance, respectively. Similar results were observed when analyzing individual coronary territories. In both pharmacological and exercise stress, automated relative quantitation demonstrated significantly more interobserver agreement than visual reads.

CONCLUSIONS

Our automated method of F-flurpiridaz relative perfusion analysis provides a quantitative, objective, and highly reproducible assessment of PET MPI in normal and CAD subjects undergoing either pharmacological or exercise stress.

摘要

背景

计算机方法使心肌灌注成像(MPI)的解释过程标准化。

方法

为了开发一种用于 F-氟比拉嗪的自动相对灌注定量方法,将所有 F-氟比拉嗪三期临床试验参与者的 F-氟比拉嗪 PET MPI 研究分为 3 组。在 40 名接受药物或运动应激的正常患者中获得计数分布。然后,在推导组中选择了另外 90 项研究。在接受者操作特性曲线分析后,使用均值以下的各种标准偏差作为有意义的 CAD 的截止值,并确定了观察者间的变异性。最后,在 548 名验证患者中,将盲法视觉读数与自动相对定量的盲法推导进行比较,比较两种方法在检测整体 CAD 时的诊断性能。

结果

两种方法在检测全球 CAD 方面的准确性相当,视觉阅读分别达到 71%和 72%,自动相对定量分别达到 72%和 68%,当分别使用 CAD≥70%或≥50%狭窄作为显著标准时。当分析各个冠状动脉区域时,也观察到了类似的结果。在药物和运动应激中,自动相对定量的观察者间一致性明显高于视觉阅读。

结论

我们的 F-氟比拉嗪相对灌注分析自动化方法为接受药物或运动应激的正常和 CAD 患者的 PET MPI 提供了一种定量、客观和高度可重复的评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f216/7936994/333981f7770f/nihms-1626938-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f216/7936994/e07f4331fa56/nihms-1626938-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f216/7936994/3ff9a6a12b31/nihms-1626938-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f216/7936994/a2743f25cb48/nihms-1626938-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f216/7936994/c60774de37d2/nihms-1626938-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f216/7936994/26935c784e72/nihms-1626938-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f216/7936994/9721aaf601a0/nihms-1626938-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f216/7936994/08bfb0fd0389/nihms-1626938-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f216/7936994/5e54dc8769b1/nihms-1626938-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f216/7936994/333981f7770f/nihms-1626938-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f216/7936994/e07f4331fa56/nihms-1626938-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f216/7936994/3ff9a6a12b31/nihms-1626938-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f216/7936994/a2743f25cb48/nihms-1626938-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f216/7936994/c60774de37d2/nihms-1626938-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f216/7936994/26935c784e72/nihms-1626938-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f216/7936994/9721aaf601a0/nihms-1626938-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f216/7936994/08bfb0fd0389/nihms-1626938-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f216/7936994/5e54dc8769b1/nihms-1626938-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f216/7936994/333981f7770f/nihms-1626938-f0009.jpg

相似文献

1
Development, diagnostic performance, and interobserver agreement of a F-flurpiridaz PET automated perfusion quantitation system.F-氟吡拉达 PET 自动灌注定量系统的开发、诊断性能和观察者间一致性。
J Nucl Cardiol. 2022 Apr;29(2):698-708. doi: 10.1007/s12350-020-02335-6. Epub 2020 Sep 7.
2
Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography.用于检测冠状动脉疾病的氟比拉嗪 F18 正电子发射断层扫描:与单光子发射计算机断层心肌灌注成像的 II 期安全性和临床比较。
J Am Coll Cardiol. 2013 Jan 29;61(4):469-477. doi: 10.1016/j.jacc.2012.11.022. Epub 2012 Dec 19.
3
Assessing myocardial perfusion in suspected coronary artery disease: rationale and design of the second phase 3, open-label multi-center study of flurpiridaz (F-18) injection for positron emission tomography (PET) imaging.评估疑似冠状动脉疾病患者的心肌灌注:氟吡达唑(F-18)注射液用于正电子发射断层扫描(PET)成像的第二项3期开放标签多中心研究的原理与设计。
J Nucl Cardiol. 2021 Jun;28(3):1105-1116. doi: 10.1007/s12350-021-02527-8. Epub 2021 Jan 31.
4
Phase-III Clinical Trial of Fluorine-18 Flurpiridaz Positron Emission Tomography for Evaluation of Coronary Artery Disease.氟[18F]氟吡拉赞正电子发射断层扫描评估冠状动脉疾病的 III 期临床试验。
J Am Coll Cardiol. 2020 Jul 28;76(4):391-401. doi: 10.1016/j.jacc.2020.05.063.
5
Flurpiridaz F-18 PET Myocardial Perfusion Imaging in Patients With Suspected Coronary Artery Disease.氟吡咯烷 F-18 PET 心肌灌注显像在疑似冠心病患者中的应用。
J Am Coll Cardiol. 2023 Oct 17;82(16):1598-1610. doi: 10.1016/j.jacc.2023.08.016.
6
Diagnostic Performance of PET Versus SPECT Myocardial Perfusion Imaging in Patients with Smaller Left Ventricles: A Substudy of the F-Flurpiridaz Phase III Clinical Trial.PET 与 SPECT 心肌灌注成像在小左心室患者中的诊断性能:F-氟吡拉齐 III 期临床试验的子研究。
J Nucl Med. 2021 Jun 1;62(6):849-854. doi: 10.2967/jnumed.120.252007. Epub 2020 Nov 27.
7
18F-flurpiridaz positron emission tomography segmental and territory myocardial blood flow metrics: incremental value beyond perfusion for coronary artery disease categorization.18F-氟吡拉齐正电子发射断层扫描节段性和区域性心肌血流指标:在冠状动脉疾病分类方面,对灌注的补充价值。
Eur Heart J Cardiovasc Imaging. 2022 Nov 17;23(12):1636-1644. doi: 10.1093/ehjci/jeab267.
8
Absolute quantitation of myocardial blood flow in human subjects with or without myocardial ischemia using dynamic flurpiridaz F 18 PET.使用动态氟吡哒唑F 18 PET对有或无心肌缺血的人类受试者的心肌血流进行绝对定量。
J Nucl Med. 2014 Sep;55(9):1438-44. doi: 10.2967/jnumed.114.141093. Epub 2014 Jul 28.
9
Improvement in PET myocardial perfusion image quality and quantification with flurpiridaz F 18.氟吡拉达 F18 改善 PET 心肌灌注图像质量和定量分析。
J Nucl Cardiol. 2012 Feb;19 Suppl 1:S38-45. doi: 10.1007/s12350-011-9487-4.
10
Rest/stress myocardial perfusion imaging by positron emission tomography with F-Flurpiridaz: A feasibility study in mice.正电子发射断层扫描用 F-Flurpiridaz 进行静息/应激心肌灌注成像:在小鼠中的可行性研究。
J Nucl Cardiol. 2023 Feb;30(1):62-73. doi: 10.1007/s12350-022-02968-9. Epub 2022 Apr 28.

引用本文的文献

1
Subendocardial quantification enhances coronary artery disease detection in F-flurpiridaz PET.心内膜下定量分析可提高F-氟吡哒嗪PET对冠状动脉疾病的检测能力。
Eur J Nucl Med Mol Imaging. 2025 Mar 5. doi: 10.1007/s00259-025-07174-6.
2
The clinical promise of F-flurpiridaz PET imaging heralds a new frontier in the diagnosis and management of coronary artery disease.F-氟吡哒唑正电子发射断层显像(PET)成像的临床前景预示着冠状动脉疾病诊断和管理的新前沿。
Nat Cardiovasc Res. 2025 Jan;4(1):1-4. doi: 10.1038/s44161-024-00587-w.
3
Electrochemical impedance spectroscopy unmasks high-risk atherosclerotic features in human coronary artery disease.

本文引用的文献

1
Phase-III Clinical Trial of Fluorine-18 Flurpiridaz Positron Emission Tomography for Evaluation of Coronary Artery Disease.氟[18F]氟吡拉赞正电子发射断层扫描评估冠状动脉疾病的 III 期临床试验。
J Am Coll Cardiol. 2020 Jul 28;76(4):391-401. doi: 10.1016/j.jacc.2020.05.063.
2
Added value of myocardial blood flow using F-flurpiridaz PET to diagnose coronary artery disease: The flurpiridaz 301 trial.使用 F-氟比拉嗪 PET 评估心肌血流对诊断冠状动脉疾病的附加值:氟比拉嗪 301 试验。
J Nucl Cardiol. 2021 Oct;28(5):2313-2329. doi: 10.1007/s12350-020-02034-2. Epub 2020 Jan 30.
3
Dosimetry, biodistribution, and safety of flurpiridaz F 18 in healthy subjects undergoing rest and exercise or pharmacological stress PET myocardial perfusion imaging.
电化学阻抗谱揭示了人类冠状动脉疾病中的高风险动脉粥样硬化特征。
FASEB J. 2024 Sep 30;38(18):e70069. doi: 10.1096/fj.202401200R.
4
The role of cardiac PET in diagnosis and prognosis of patients with ischemia with no obstructive coronary arteries (INOCA).心脏正电子发射断层扫描(PET)在无阻塞性冠状动脉(INOCA)的缺血患者诊断和预后评估中的作用。
Am Heart J Plus. 2024 May 18;43:100399. doi: 10.1016/j.ahjo.2024.100399. eCollection 2024 Jul.
5
Progress of F-flurpiridaz in Clinical Trials.F-氟吡哒唑的临床试验进展。
Ann Nucl Cardiol. 2023;9(1):91-93. doi: 10.17996/anc.23-00011. Epub 2023 Oct 31.
6
Review of cardiovascular imaging in the Journal of Nuclear Cardiology 2022: positron emission tomography, computed tomography, and magnetic resonance.《核医学杂志》2022 年心血管成像综述:正电子发射断层扫描、计算机断层扫描和磁共振成像。
J Nucl Cardiol. 2023 Jun;30(3):941-954. doi: 10.1007/s12350-023-03283-7. Epub 2023 May 19.
7
Rest/stress myocardial perfusion imaging by positron emission tomography with F-Flurpiridaz: A feasibility study in mice.正电子发射断层扫描用 F-Flurpiridaz 进行静息/应激心肌灌注成像:在小鼠中的可行性研究。
J Nucl Cardiol. 2023 Feb;30(1):62-73. doi: 10.1007/s12350-022-02968-9. Epub 2022 Apr 28.
8
18F-flurpiridaz positron emission tomography segmental and territory myocardial blood flow metrics: incremental value beyond perfusion for coronary artery disease categorization.18F-氟吡拉齐正电子发射断层扫描节段性和区域性心肌血流指标:在冠状动脉疾病分类方面,对灌注的补充价值。
Eur Heart J Cardiovasc Imaging. 2022 Nov 17;23(12):1636-1644. doi: 10.1093/ehjci/jeab267.
9
Novel Tracers and Radionuclides in PET Imaging.正电子发射断层扫描中的新型示踪剂和放射性核素
Radiol Clin North Am. 2021 Sep;59(5):887-918. doi: 10.1016/j.rcl.2021.05.012.
10
Diagnostic Performance of PET Versus SPECT Myocardial Perfusion Imaging in Patients with Smaller Left Ventricles: A Substudy of the F-Flurpiridaz Phase III Clinical Trial.PET 与 SPECT 心肌灌注成像在小左心室患者中的诊断性能:F-氟吡拉齐 III 期临床试验的子研究。
J Nucl Med. 2021 Jun 1;62(6):849-854. doi: 10.2967/jnumed.120.252007. Epub 2020 Nov 27.
氟吡拉达 F18 在健康受试者行静息和运动或药物负荷 PET 心肌灌注显像中的剂量学、生物分布和安全性。
J Nucl Cardiol. 2019 Dec;26(6):2018-2030. doi: 10.1007/s12350-018-01484-z. Epub 2018 Nov 28.
4
Cardiac PET perfusion: prognosis, risk stratification, and clinical management.心脏PET灌注:预后、风险分层及临床管理。
Semin Nucl Med. 2014 Sep;44(5):344-57. doi: 10.1053/j.semnuclmed.2014.05.003.
5
Cardiac PET perfusion tracers: current status and future directions.心脏PET灌注示踪剂:现状与未来方向。
Semin Nucl Med. 2014 Sep;44(5):333-43. doi: 10.1053/j.semnuclmed.2014.06.011.
6
Absolute quantitation of myocardial blood flow in human subjects with or without myocardial ischemia using dynamic flurpiridaz F 18 PET.使用动态氟吡哒唑F 18 PET对有或无心肌缺血的人类受试者的心肌血流进行绝对定量。
J Nucl Med. 2014 Sep;55(9):1438-44. doi: 10.2967/jnumed.114.141093. Epub 2014 Jul 28.
7
Prognostic value of PET myocardial perfusion imaging in obese patients.PET 心肌灌注成像在肥胖患者中的预后价值。
JACC Cardiovasc Imaging. 2014 Mar;7(3):278-87. doi: 10.1016/j.jcmg.2013.12.008. Epub 2014 Feb 19.
8
Patient-centered imaging: shared decision making for cardiac imaging procedures with exposure to ionizing radiation.以患者为中心的成像:针对接受电离辐射的心脏成像检查进行共同决策。
J Am Coll Cardiol. 2014 Apr 22;63(15):1480-9. doi: 10.1016/j.jacc.2013.10.092. Epub 2014 Feb 13.
9
Clinical decision support systems in myocardial perfusion imaging.心肌灌注成像中的临床决策支持系统
J Nucl Cardiol. 2014 Jun;21(3):427-39; quiz 440. doi: 10.1007/s12350-014-9857-9. Epub 2014 Jan 31.
10
Serial myocardial perfusion imaging: defining a significant change and targeting management decisions.连续心肌灌注成像:定义显著变化并确定管理决策。
JACC Cardiovasc Imaging. 2014 Jan;7(1):79-96. doi: 10.1016/j.jcmg.2013.05.022.